Atlanta, GA – May 2025 – In a notable moment for the biotechnology and academic communities in Georgia, MAGISNAT OMICS LLC, a biotechnology spin-off operating in the field of omics sciences, marked its first anniversary with two high-profile events held on May 13 and 14. The events, which took place at the Georgia State Capitol and Atlanta Tech Park, brought together institutional leaders, researchers, academics, and entrepreneurs to reflect on the progress made over the past year and to discuss future directions in biomedical innovation, with a particular focus on omics-based technologies and patented solutions.
The first of the two gatherings was held at the Georgia State Capitol, a setting that added symbolic and strategic weight to the discussions. Positioned at the center of legislative and political decision-making in Georgia, the Capitol offered a unique venue to explore how scientific innovation can align with public policy, institutional development, and community health goals. Within this context, MAGISNAT presented its work in the area of multi-omics science—an emerging interdisciplinary approach that integrates genomic, metabolomic, proteomic, microbiomic, and environmental data to generate a comprehensive understanding of individual health profiles. The aim is to enable more precise, preventive strategies against chronic non-communicable diseases, which continue to be a major burden on healthcare systems globally.
The event was attended by a qualified audience comprising scientists, entrepreneurs, and representatives from public institutions. Among the contributions, the presentation by Dr. Vishnu Suppiramaniam, Associate Dean and Professor at Kennesaw State University, provided a thoughtful reflection on the role of academic institutions in supporting scientific progress and enabling the transfer of research outcomes into practical applications. Dr. Suppiramaniam noted that universities such as Kennesaw State function not only as centers for education and research but also as contributors to economic development, especially when they engage in structured collaborations with biotechnology spin-offs such as MAGISNAT. His intervention highlighted the reciprocal value of these interactions: students gain access to applied scientific contexts; academic staff have opportunities to conduct research with practical relevance; and spin-offs benefit from academic support in terms of expertise, infrastructure, and institutional credibility.
The potential collaboration between Kennesaw State University and MAGISNAT was discussed as a possible example of university–industry cooperation with shared scientific interests. Dr. Suppiramaniam noted that some of MAGISNAT’s ongoing projects and patent activities align with the research directions pursued at Kennesaw State University. This alignment may offer opportunities for future joint initiatives, including collaborative research, student training, and technology transfer. Such a framework could support the development of translational research efforts and contribute to the advancement of regional expertise in the biotechnology sector.
from Kennesaw State University, Atlanta, Georgia.
In addition to Dr. Suppiramaniam, the Capitol event featured several key MAGISNAT representatives, including Dr. Stephen Thadeus Connelly, MAGISNAT co-founder and Professor at the University of California, San Francisco. Dr. Connelly spoke about the role of translational research in today’s biomedical landscape, stressing the importance of building bridges between basic science and real-world application. Dr. Matteo Bertelli, President of MAGISNAT, provided an overview of the company’s most recent patents, highlighting the potential impact of each innovation. Dr. Kevin Donato, CEO of MAGISNAT, outlined the strategic vision for scaling scientific results into clinical and wellness platforms, while Dr. Giuseppe Oriani, Chairman of Savills Investment Management SGR, discussed the financial and investment opportunities connected to the spin-off model, illustrating how biotech entrepreneurship can attract private capital and build sustainable business models.
Institutional attendees included Neal VanMarter, representative of U.S. Senator Jon Ossoff’s office, who offered supportive remarks on behalf of the Senator; Filiberto Calascibetta, Honorary Consul of Italy in Atlanta, who reinforced the value of international cooperation; Nick Masino, President and CEO of the Gwinnett Chamber of Commerce; and Robin Bienfait, Founder and CEO of Atlanta Tech Park. The session was moderated by Dr. Pietro Chiurazzi, Associate Professor at the Catholic University of Rome and MAGISNAT co-founder.
The second event, held on May 14 at Atlanta Tech Park in Peachtree Corners, focused on the scientific and technological developments achieved during MAGISNAT’s initial year of activity. Atlanta Tech Park, known for supporting startups and high-tech innovation, served as a suitable venue for presenting the company’s research projects and recently filed patents to an audience composed of scientists, entrepreneurs, and representatives from the policy and innovation sectors. The presentations provided an overview of the scientific rationale and potential applications behind five projects currently under patent by MAGISNAT researchers.
Among the technologies presented was a diagnostic platform based on mass spectrometry and breath analysis, designed to evaluate respiratory inflammation linked to environmental pollutants, with potential applications in public health surveillance. Another innovation involved a neuromodulation system utilizing targeted intranasal delivery of neuroactive molecules to influence appetite regulation. The researchers also presented a model to study protein glycosylation stress associated with dietary imbalances, along with a set of proprietary bioinformatic tools developed to analyze multi-omic data in clinical research contexts. The fifth project introduced a therapeutic approach aimed at limiting subcutaneous fat proliferation in individuals with lipedema, through inhibition of the enzyme AKR1C2.
Scientific contributions came from MAGISNAT researchers including Dr. Kristjana Dhuli, Dr. Cecilia Micheletti, Dr. Alessandro Macchia, and Dr. Jurgen Kaftalli, who elaborated on the development and potential of each patent. Their presentations demonstrated the company’s commitment to producing technologies that are not only scientifically robust but also clinically relevant and scalable.
Institutional greetings at the Tech Park event were delivered by Robin Bienfait, Nashlee Young (Director of Operations, Atlanta Tech Park), Bertrand Lapoire (Economic Development Director, City of Peachtree Corners), and Nick Masino, once again emphasizing the regional support for innovation in biotech and health sciences.
Across both events, the underlying message was clear: innovation in omics science, when supported by strong academic collaboration and a favorable institutional environment, has the potential to deliver real impact. As a spin-off rooted in scientific rigor and entrepreneurial spirit, MAGISNAT stands as an example of how research can be translated into health solutions with both commercial and societal value. With a growing portfolio of patents and a vibrant network of partnerships, the company looks ahead to deepening its role in shaping the future of personalized medicine.
